We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Boehringer Ingelheim and the BioMed X Innovation Center are using crowdsourcing to assemble a research team to identify new approaches to treat chronic obstructive pulmonary disease. Read More
The FDA awarded a three-year contract to the American Society of Health-System Pharmacists to develop and implement standardized concentrations for intravenous and oral liquid medicines as part of the agency’s Safe Use Initiative. Read More
Pfizer’s oral Xeljanz sent more patients suffering from moderate to severe ulcerative colitis into remission, meeting primary endpoints in two Phase 3 clinical trials, the company reported Monday. Read More
The FDA is evaluating the potential risks of prescribing tramadol for children 17 years and younger because it may cause slowed or difficult breathing. The opioid drug is not approved for use in children, but is being prescribed “off-label.” Read More
The FDA has awarded research grants totaling more than $19 million to boost the development of products to treat 17 different rare diseases, many of which have little or no available treatment options. Read More
The U.S. government is awarding $62 million to Regeneron Pharmaceuticals and Inovio Pharmaceuticals to support their ongoing development of novel Ebola virus treatments. Read More
A 5,000 percent price hike for the only drug indicated for treating a specific type of parasitic infection – and one that is critical for patients with lowered immune systems – is drawing howls from the public. Read More